{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-012133","form_type":"8-K","ticker":null,"cik":"0001642375","company_name":"Guardion Health Sciences, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.388606+00:00","generated_at":"2026-06-04T04:43:31.754308+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Guardion Health Sciences FY2023 revenue up 10.8% to $12.2M; selling main asset and planning dissolution","bullets":["FY2023 revenue $12.2M (+10.8% YoY); net income $0.2M vs $(14.9M) loss prior year; EPS $0.12.","Viactiv product line generated $11.9M (+11.9% YoY), representing 97.2% of total revenue.","On Jan 30, 2024, agreed to sell Activ Nutritional (owner of Viactiv) for $17.2M cash, subject to stockholder approval.","Board proposes voluntary dissolution and liquidation after sale closes; special meeting set for May 23, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-012133","json":"https://secwatch.observer/filing/0001493152-24-012133.json","markdown":"https://secwatch.observer/filing/0001493152-24-012133.md","text":"https://secwatch.observer/filing/0001493152-24-012133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642375/000149315224012133/0001493152-24-012133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642375/000149315224012133/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:43:31.754308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87e23d855da346ccee0b2ecce9b48384182aa350","claim":"Guardion Health Sciences, Inc. reported the year ended December 31, 2023 results: revenue $12,248,550, net income $158,033, EPS $0.12.","evidence_excerpt":"31, 2023. The Company also provided a corporate update to stockholders. Financial highlights for the year ended December 31, 2023 include the following: ● Total revenue was $12,248,550 for the year ended December 31, 2023, as compared to $11,049,772 for the year ended December 31, 2022, an increase of $1,198,778, or 10.8%. The Viactiv ® product line generated","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642375/000149315224012133/0001493152-24-012133-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$12,248,550"},{"label":"Net income","value":"$158,033"},{"label":"EPS","value":"$0.12"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}